Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

Molecular Cancer Therapeutics

Volumn 8, Issue 6, 2009, Pages 1484-1493

  Messersmith, Wells A ^a   Rajeshkumar, N V ^b   Aik, Choon Tan ^b   Xiao, Fei Wang ^b   Diesl, Veronica ^c   Choe, Sung E ^c   Follettie, Max ^c   Coughlin, Christina ^c   Boschelli, Frank ^d   Garcia Garcia, Elena ^e   Lopez Rios, Fernando ^e   Jimeno, Antonio ^a   Hidalgo, Manuel ^b,e  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d WYETH RESEARCH   (United States)

^e Hospital Madrid Norte Sanchinarro   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BOSUTINIB; CAVEOLIN 1; DASATINIB; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; STAT5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; BLOTTING, WESTERN; CAVEOLIN 1; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NITRILES; ONCOGENE PROTEIN PP60(V-SRC); PANCREATIC NEOPLASMS; QUINOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649366381     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0075     Document Type: Article

References (40)

1. American Cancer Society, Cancer Facts and Figures 2008. American Cancer Society (Atlanta, GA).
2. Yeo TP, Hruban RH, Leach SD, et al. Pancreatic cancer. Curr Probl Cancer 2002;26:176-275.
3. Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413 (Pubitemid 27251144)
4. Moore MJ GD, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCICCTG]. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 1.
5. Cunningham D CI, Stocken D, et al. GEM-CAP: PHASE III radnomised comparison of gemcitabine with gemcitabine plus capecitabine in patients with advanced pancreas cancer. ECCO 2005, #PS11.
6. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-4661 (Pubitemid 44297818)
7. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-5642
8. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000;60:1091-1099
9. Park SI, Shah AN, Zhang J, Gallick GE. Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets 2007;11:1207-1217 (Pubitemid 47527325)
10. Lutz MP, Esser IB, Flossmann-Kast BB, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243:503-508 (Pubitemid 28414054)
11. Kayali AG, Stotland A, Gunst KV, et al. Growth factor-induced signaling of the pancreatic epithelium. J Endocrinol 2005;185:45-56. (Pubitemid 40585066)
12. Masamune A, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells. World J Gastroenterol 2005;11:3385-3391 (Pubitemid 40873243)
13. Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004;10:8028-8036 (Pubitemid 39587544)
14. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-972 (Pubitemid 43327748)
15. Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112:859-871 (Pubitemid 36378887)
16. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207-3213 (Pubitemid 46572505)
17. Messersmith WA KS, Hewes BA, et al. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 3552.
18. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-2238 (Pubitemid 46424242)
19. Wang XD, Reeves K, Luo FR, et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007;8:R255. (Pubitemid 351917494)
20. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537
21. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-15550 (Pubitemid 41528093)
22. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006;34:D354-7.
23. Tan AC, Naiman DQ, Xu L, Winslow RL, Geman D. Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics 2005;21:3896-3904 (Pubitemid 41535505)
24. Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005;65:5358-5364 (Pubitemid 40827349)
25. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007;67:1580-1588 (Pubitemid 46383382)
26. Li S, Couet J, Lisanti MP. Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996;271:29182-29190 (Pubitemid 26382628)
27. Venema VJ, Ju H, Zou R, Venema RC. Interaction of neuronal nitricoxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J Biol Chem 1997;272:28187-28190 (Pubitemid 27517753)
28. Serrels A, Macpherson IR, Evans TR, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006;5:3014-3022 (Pubitemid 46092042)
29. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRCkin ase for survival. Cancer Res 2007;67:2800-2808 (Pubitemid 46548969)
30. Tsao AS, He D, Saigal B, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007;6:1962-1972 (Pubitemid 47052486)
31. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS- 354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-6932 (Pubitemid 41428750)
32. Chen TGJ, Taylor CC. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? Anti-Cancer Drugs 2006;17:123-131.
33. Boschelli DH, Wu B, Barrios Sosa AC, Chen JJ, Golas JM, Boschelli F. Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)amino]- 2-heteroaryl-thieno[3,2-b]pyridine -6-carbonitriles. Bioorg Med Chem Lett 2005;15:4681-4684
34. Hussain SF, Kong LY, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007;67:9630-9636 (Pubitemid 47621208)
35. Jimeno ASA, Karikari C, et al. A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA). J Clin Oncol 2008;26:.
36. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005;288:C494-506. (Pubitemid 40229478)
37. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 2008;27:715-735
38. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol 2008;84:177-189 (Pubitemid 351323417)
39. Cordes N, Frick S, Brunner TB, et al. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 2007;26:6851-6862 (Pubitemid 47609078)
40. Suzuoki M, Miyamoto M, Kato K, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002;87:1140-1144 (Pubitemid 35418110)